[HTML][HTML] Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in …

S Zhou, L Xie, C Zhou, Y Zhao, L Wang, S Ding… - European Journal of …, 2023 - Elsevier
Background Keverprazan is a novel potassium-competitive acid blocker for the treatment of
acid-related diseases. Aims To evaluate the safety, pharmacokinetics, pharmacodynamics …

Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer with or without Helicobacter pylori Infection: A …

M Ouyang, S Zou, Q Cheng, X Shi, Y Zhao, M Sun - Pharmaceuticals, 2024 - mdpi.com
Novel potassium-competitive acid blockers (P-CABs) have emerged as effective acid-
suppressive drugs in recent years, replacing proton pump inhibitors (PPIs). We aim to …

Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: a systematic review and network meta-analysis

Y Liu, Z Gao, XH Hou - Therapeutic Advances in …, 2024 - journals.sagepub.com
Background: Proton-pump inhibitors (PPIs) and potassium-competitive acid blockers (P-
CABs) are recommended for erosive esophagitis (EE), with good safety and tolerance …

Randomized, Double-blind, Active-controlled Phase 3 Study to Evaluate Efficacy and Safety of Zastaprazan compared to Esomeprazole in Erosive Esophagitis

JH Oh, HS Kim, DY Cheung, HL Lee… - Official journal of the …, 2022 - journals.lww.com
METHODS: A phase III, multicenter, randomized, double-blind, non-inferiority clinical study
was conducted with 300 subjects with confirmed EE. Subjects were randomized to receive …